Surprise Federal Drug Rule Requires Price Transparency from Insurers
Health insurance companies will have to give their customers estimated out-of-pocket costs for prescription drugs and disclose to the public [...]
ICER Recommendations Can Be Influenced With the Right Evidence
Based on previous ICER reports, when a pharma product goes through an ICER assessment, there is an extremely high chance [...]
The Emergence of ICER in American Pharma
Joe Biden recently suggested that Medicare drug-price negotiations should follow the German model where negotiations between government and drugmakers are informed [...]
A Third of States Weighing Moves to Spend Less on Drugs
As they grapple with the economic fallout of Covid-19, about 1/3rd of U.S. states are looking for different ways to [...]
To Curb High Out-of-Pocket Costs, Drug Rebates Should Benefit Consumers
The Center for Medical Economics and Innovation at the Pacific Research Institute released a brief that concluded that one principal [...]
US Drug Pricing Reform Post-Election
COVID is going to take priority over drug pricing as a policy focus regardless of the outcome of the US [...]
Drug Pricing Bill Unlikely With Split Congress
The Republican-led Senate is not likely not go along with Democrats' plan to let Medicare leverage its substantial buying power [...]
Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States
Cost-effectiveness analysis is an important tool for informing treatment coverage and pricing decisions. However, there is no consensus on whether [...]
[Podcast] A Prescription for Fair Drug Pricing
ICER has announced the launch of a new podcast series entitled “A Prescription for Fair Drug Pricing.” In this series [...]
ICER Launches New Podcast: A Prescription for Fair Drug Pricing
America’s got a fever. And the only prescription? More cowbell—and fair drug pricing. To that end, ICER announced the launch [...]
Bureaucrats May Stop Life-saving Meds from Reaching Canada
If Canadian bureaucrats on the Patent Medicine Prices Review Board (PMPRB) get their way, innovative new drugs and vaccines may not come [...]
[Podcast] Telehealth, Standardizing Care, and Drug Prices in Oncology With Dr. Vincent Rajkumar
Tune to this podcast for a discussion on telehealth in oncology with Vincent Rajkumar, MD. As he lends his insights [...]
WHO’s New Pricing Policy Guideline Makes Medicines More Affordable
A new WHO guideline aims to help governments overcome the barrier of high prices for pharma products, enabling them to [...]
The Trouble With List Prices
This week, the RAND Corporation issued a new report highlighting that US list prices on insulin are 8.1 times higher than [...]
Pharmaceuticals Purchasing: Lessons From Other Countries
Dr. James Robinson of UC Berkeley cautions against the widening gulf and conflict between the increasing prices set by drugmakers [...]
For Shame: Congress Accuses Novartis, Amgen and Mallinckrodt of Price-Gouging
Amgen, Mallinckrodt, and Novartis are now in the same boat as Celgene and Teva. A congressional probe released several reports [...]
Hospitals and Outpatient Care Are the Primary Drivers of Sky-high US Healthcare Costs
Although drug prices are at the forefront of many voters’ minds, they are not actually the main reason the U.S. [...]
ICER Condemns Monopoly Pricing of Trikafta Despite High Marks for Efficacy
While the therapeutic value of Vertex Pharmaceuticals’ triplet drug Trikafta for cystic fibrosis is indisputable, the Institute for Clinical and [...]
2 of 3 Americans Reveal Healthcare Insecurity and Problems Paying for Prescription Drugs
The COVID-19 pandemic has caused severe healthcare insecurity for millions of Americans, according to CoverMyMeds’ 2020 Medication Access Report. As [...]
Medicare turns 55, and now’s the time to look at Part D – did it work?
On July 30, 1965, President Lyndon B. Johnson signed into law legislation that established the Medicare and Medicaid programs. The [...]
A Look at How Germany Structures Drug Purchasing
James Robinson in a recent perspective piece published in NEJM looks at how Germany purchases medicines. Germany's system, he writes, [...]
PBM Report Suggests Wider Use of Tools Can Lead to $1 Trillion in Savings
A new study by Visante, funded by the Pharmaceutical Care Management Association (PCMA), suggests greater use of PBM tools could [...]
